Dr. brahm segal appointed to nextcure scientific advisory board; nextcure and roswell park shared nonclinical data on the impact of nc410 blockade on neutrophil-mediated t cell suppression at the 24th translational research cancer centers consortium annual meeting

Beltsville, md., june 22, 2022 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that collaborator brahm segal, m.d., of roswell park comprehensive cancer center shared nonclinical data from a research study that models the ability of nc410 to block neutrophil-mediated suppression of t cells in a tumor microenvironment (tme) at the 24th translational research cancer centers consortium annual meeting. in addition, nextcure appointed dr. segal to its scientific advisory board (sab).
NXTC Ratings Summary
NXTC Quant Ranking